Drug intelligence / Profile preview

umbilical cord mesenchymal stem cells + autologous bone marrow mononuclear cells

Development stage
Unknown
Lead developer
900th Hospital of Joint Logistics Support Force of PLA
Modality
Stem Cell Therapies → Cell Therapies
Administration
Intra-arterial
01

Overview

This experimental cell therapy, developed by Fuzhou General Hospital, is a combination treatment consisting of umbilical cord-derived mesenchymal stem cells (UC-MSCs) and autologous bone marrow mononuclear cells (aBM-MNCs). Investigated primarily for the treatment of type 1 diabetes mellitus, the therapy is administered via supraselective pancreatic artery cannulation. The mechanism of action involves the immunomodulatory properties of UC-MSCs and the regenerative potential of both cell types to preserve residual beta-cell function and promote the regeneration of insulin-secreting cells. Clinical study results have indicated that the treatment is well-tolerated and can lead to improved C-peptide levels and glycemic control in responders without the need for traditional immunotherapy.

Other names
UC-MSCs and Mononuclear Cells InfusionUC-MSC + aBM-MNC

Beyond the preview

Go deeper on umbilical cord mesenchymal stem cells + autologous bone marrow mononuclear cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on umbilical cord mesenchymal stem cells + autologous bone marrow mononuclear cells.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call